Exploration of Targeted Anti-tumor Therapy

Open Access Original Article

Cola rostrata K. Schum. constituents induce cytotoxicity through reactive oxygen species generation and mitochondrial membrane depolarisation

Babatunde E. Ajayi ... Amos A. Fatokun

Published: December 28, 2023 Explor Target Antitumor Ther. 2023;4:1328–1344

DOI: https://doi.org/10.37349/etat.2023.00200

This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents

Full Text PDF

2077 25 2

Open Access Review

Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes

Chaoqun Li ... Jieer Ying

Published: December 28, 2023 Explor Target Antitumor Ther 2023;4:1310–1327

DOI: https://doi.org/10.37349/etat.2023.00199

This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer

Full Text PDF

2161 16 1

Open Access Perspective

Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?

Sabah Alaklabi ... Shipra Gandhi

Published: December 27, 2023 Explor Target Antitumor Ther. 2023;4:1301–1309

DOI: https://doi.org/10.37349/etat.2023.00198

This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer

Full Text PDF

2190 26 0

Open Access Review

Current implications and challenges of artificial intelligence technologies in therapeutic intervention of colorectal cancer

Kriti Das ... Chakresh Kumar Jain

Published: December 27, 2023 Explor Target Antitumor Ther. 2023;4:1286–1300

DOI: https://doi.org/10.37349/etat.2023.00197

This article belongs to the special issue Artificial Intelligence for Precision Oncology

Full Text PDF

2570 34 5

Open Access Review

Post-translational modulation of cell signalling through protein succinylation

Katharina F. Kubatzky ... Dayoung Yu

Published: December 27, 2023 Explor Target Antitumor Ther. 2023;4:1260–1285

DOI: https://doi.org/10.37349/etat.2023.00196

This article belongs to the special issue Posttranslational Modifications in Health and Disease

Full Text PDF

5119 60 6

Open Access Review

Telehealth in breast cancer following the coronavirus disease 2019 pandemic

Jean Zeghondy ... Barbara Pistilli

Published: December 26, 2023 Explor Target Antitumor Ther. 2023;4:1249–1259

DOI: https://doi.org/10.37349/etat.2023.00195

This article belongs to the special issue COVID-19 and Cancer

Full Text PDF

1653 13 0

Open Access Review

Recent advancements in targeted protein knockdown technologies—emerging paradigms for targeted therapy

Mansi Joshi ... Abhijit De

Published: December 26, 2023 Explor Target Antitumor Ther. 2023;4:1227–1248

DOI: https://doi.org/10.37349/etat.2023.00194

This article belongs to the special issue Posttranslational Modifications in Health and Disease

Full Text PDF

3192 68 3

Open Access Original Article

Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing tumour protein 53 gene status

Ali JN Duabil ... George DD Jones

Published: December 21, 2023 Explor Target Antitumor Ther. 2023;4:1210–1226

DOI: https://doi.org/10.37349/etat.2023.00193

Full Text PDF

1925 25 0

Open Access Original Article

Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer

Vignesh Sivaganesh, Bela Peethambaran

Published: December 20, 2023 Explor Target Antitumor Ther. 2023;4:1188–1209

DOI: https://doi.org/10.37349/etat.2023.00192

Full Text PDF

2277 27 3

Open Access Case Report

Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?

Sviatoslav Chekhun ... Maria Saigí

Published: December 13, 2023 Explor Target Antitumor Ther. 2023;4:1182–1187

DOI: https://doi.org/10.37349/etat.2023.00191

Full Text PDF

2052 20 0

Open Access Review

Targeting cancer stem cell plasticity in triple-negative breast cancer

Zhengwang Guo, Shuyan Han

Published: December 11, 2023 Explor Target Antitumor Ther. 2023;4:1165–1181

DOI: https://doi.org/10.37349/etat.2023.00190

This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer

Full Text PDF

2761 40 3

Open Access Case Report

Unexpected “Lazarus response” to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer

Alexey V. Emshanov ... Evgeny N. Imyanitov

Published: December 06, 2023 Explor Target Antitumor Ther. 2023;4:1157–1164

DOI: https://doi.org/10.37349/etat.2023.00189

Full Text PDF

1650 22 1

Open Access Original Article

Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy

Witida Laopajon ... Watchara Kasinrerk

Published: December 06, 2023 Explor Target Antitumor Ther. 2023;4:1145–1156

DOI: https://doi.org/10.37349/etat.2023.00188

This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer

Full Text PDF

2188 28 0

Open Access Meta-Analysis

Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis

Marco Filetti ... Gennaro Daniele

Published: December 01, 2023 Explor Target Antitumor Ther. 2023;4:1136–1144

DOI: https://doi.org/10.37349/etat.2023.00187

Full Text PDF

2162 55 0